Interestingly, compared to RAS-wildtype t(4;11)+ ALL cases, the RAS-mutant t(4;11)+ infant ALL cases were significantly more sensitive to all MEK inhibitors (Figure 2A) with median IC50 values of <0.1 μM for MEK162 and Selumetinib and <0.01 μM for Trametinib (Figure 2B). This evidence concerns the gene MAP2K7 and acute lymphoblastic leukemia.